Literature DB >> 15671080

Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells.

Mikiko Ito1, Yuko Sakai, Mari Furumoto, Hiroko Segawa, Sakiko Haito, Setsuko Yamanaka, Rie Nakamura, Masashi Kuwahata, Ken-ichi Miyamoto.   

Abstract

Fibroblast growth factor-23 (FGF-23) has been recently identified as playing an important pathophysiological role in phosphate homeostasis and vitamin D metabolism. To elucidate the precise physiological regulation of FGF-23, we characterized the mouse FGF-23 5'-flanking region and analyzed its promoter activity. The 5'-flanking region of the mouse FGF-23 gene contained a TFIID site (TATA box) and several putative transcription factor binding sites, including MZF1, GATA-1 and c-Ets-1 motifs, but it did not contain the typical sequences of the vitamin D response element. Plasmids encoding 554-bp (pGL/-0.6), 364-bp (pGL/-0.4) and 200-bp (pGL/-0.13) promoter regions containing the TFIID element and +1-bp fragments drove the downstream expression of a luciferase reporter gene in transfection assays. We also found that FGF-23 mRNA was expressed in K-562 erythroleukemia cell lines but not in MC3T3-E1, Raji, or Hep G2 human carcinoma cells. Treatment with 1,25-dihydroxyvitamin D3 in the presence of high phosphate markedly stimulated pGL/-0.6 activity, but calcium had no effect. In addition, the plasma FGF-23 levels were affected by the dietary and plasma inorganic phosphate concentrations. Finally, the levels of plasma FGF-23 in vitamin D receptor-null mice were significantly lower than in wild-type mice. The presents study demonstrated that vitamin D and the plasma phosphate level are important regulators of the transcription of the mouse FGF-23 gene.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15671080     DOI: 10.1152/ajpendo.00502.2004

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  45 in total

Review 1.  Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αKlotho).

Authors:  Emily G Farrow; Erik A Imel; Kenneth E White
Journal:  Best Pract Res Clin Rheumatol       Date:  2011-10       Impact factor: 4.098

Review 2.  The role of vitamin D in the FGF23, klotho, and phosphate bone-kidney endocrine axis.

Authors:  Mark R Haussler; G Kerr Whitfield; Ichiro Kaneko; Ryan Forster; Rimpi Saini; Jui-Cheng Hsieh; Carol A Haussler; Peter W Jurutka
Journal:  Rev Endocr Metab Disord       Date:  2012-03       Impact factor: 6.514

3.  FGF23 beyond mineral metabolism: a bridge to cardiovascular disease.

Authors:  Tobias E Larsson
Journal:  Clin J Am Soc Nephrol       Date:  2011-12       Impact factor: 8.237

4.  Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23.

Authors:  Sherri-Ann M Burnett-Bowie; Benjamin Z Leder; Maria P Henao; Chantel M Baldwin; Douglas L Hayden; Joel S Finkelstein
Journal:  Clin J Am Soc Nephrol       Date:  2012-02-02       Impact factor: 8.237

5.  Relation between fibroblast growth factor-23, body weight and bone mineral density in elderly men.

Authors:  R Marsell; M A I Mirza; H Mallmin; M Karlsson; D Mellström; E Orwoll; C Ohlsson; K B Jonsson; O Ljunggren; T E Larsson
Journal:  Osteoporos Int       Date:  2008-10-31       Impact factor: 4.507

Review 6.  Phosphate Toxicity in CKD: The Killer among Us.

Authors:  Cynthia S Ritter; Eduardo Slatopolsky
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-10       Impact factor: 8.237

Review 7.  Arterial stiffness, vascular calcification and bone metabolism in chronic kidney disease.

Authors:  János Nemcsik; István Kiss; András Tislér
Journal:  World J Nephrol       Date:  2012-02-06

8.  Oral vitamin D3 supplementation increases serum fibroblast growth factor 23 concentration in vitamin D-deficient patients: a systematic review and meta-analysis.

Authors:  N Charoenngam; P Rujirachun; M F Holick; P Ungprasert
Journal:  Osteoporos Int       Date:  2019-08-01       Impact factor: 4.507

9.  Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease.

Authors:  P Manghat; W D Fraser; A S Wierzbicki; I Fogelman; D J Goldsmith; G Hampson
Journal:  Osteoporos Int       Date:  2009-12-09       Impact factor: 4.507

10.  1alpha,25-dihydroxyvitamin D3 acts predominately in mature osteoblasts under conditions of high extracellular phosphate to increase fibroblast growth factor 23 production in vitro.

Authors:  Ryoko Yamamoto; Tomoko Minamizaki; Yuji Yoshiko; Hirotaka Yoshioka; Kazuo Tanne; Jane E Aubin; Norihiko Maeda
Journal:  J Endocrinol       Date:  2010-06-08       Impact factor: 4.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.